While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public companies.
Unfortunately, after a solid first quarter, the biotech IPO market has slowed considerably into the second quarter. While some companies are still able to get out -- Corium (NASDAQ:CORI), Cerulean Pharma (NASDAQ:CERU), and Adamas Pharmaceuticals (NASDAQ:ADMS) to name a few -- they're pricing below their ranges and aren't taking off once they hit the public markets, like we saw previously.
In the video below, senior biotech specialist Brian Orelli and health care bureau chief Max Macaluso discuss what the slowdown means for Corium, Cerulean Pharma, and Adamas Pharmaceuticals, as well as the companies still in the IPO queue, including MannKind (NASDAQ:MNKD) competitor Dance Pharma, which filed for a $75 million IPO this month.
This 2014 pick could be your next ten-bagger
Every year, The Motley Fool's chief investment officer hand-picks one stock with amazing potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303%! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
Brian Orelli Max Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.